

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Emanuel Gancia	12/15/2010
Robert Andrew Heald	12/15/2010
Philip Jackson	12/09/2010
Stephen Price	12/14/2010
RECEIVING PARTY DATA	
Name:	Argenta Discovery 2009 Limited
Street Address:	8/9 Spire Green Centre
City:	Flex Meadow, Harlow Essex
State/Country:	UNITED KINGDOM
Postal Code:	CM19 5TR
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	12998000
CORRESPONDENCE DATA	
Fax Number:	(650)952-9881
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	(650) 225-8018
Email:	buckwalter.brian@gene.com
Correspondent Name:	Brian L. Buckwalter
Address Line 1:	1 DNA Way
Address Line 2:	Legal Department, MS \$9
Address Line 4:	South San Francisco, CALIFORNIA 94080-4990
ATTORNEY DOCKET NUMBER:	P4225R1
NAME OF SUBMITTER:	Brian L. Buckwalter
Total Attachments: 2	

CH \$40.00 12998000

501404249

**PATENT
 REEL: 025627 FRAME: 0446**

source=P4225R1_Argenta_to_Genentech_Assignment#page1.tif

source=P4225R1_Argenta_to_Genentech_Assignment#page2.tif

ASSIGNMENT

06920289
3671653
5
WHEREAS, ARGENTA DISCOVERY 2009 LIMITED, a company registered in England with number 3671653, whose registered office and principal place of business is 8/9 Spire Green Centre, Flex Meadow, Harlow, Essex CM195TR (hereinafter "ASSIGNOR") has full right, title, and interest in and to a new and useful invention in:

BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS

for which US application No. _____ (if received, Docket No. P4225R1 US) for Letters Patent and to International Application No. PCT/US2009/049449 (Docket No. P4225R1), filed by them on July 1, 2009, both which claim priority to US provisional application number 61/077,432, filed on July 1, 2008; and

WHEREAS, GENENTECH, INC., a corporation organized and existing under and by virtue of the laws of the State of Delaware, having a place of business at 1 DNA Way, South San Francisco, California 94080-4990, is desirous of acquiring an interest in and to said invention, and in and to the Letters Patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

That for good and valuable consideration the receipt of which is hereby acknowledged, the said ASSIGNOR has and does hereby sell, assign, transfer and set over unto the said GENENTECH, INC., its successors and assigns, the full and exclusive right, title and interest including all rights under the Paris Convention for the Protection of Industrial Property, in and to said invention, and in and to any and all Letters Patents to be granted and issued therefor or any continuation, division, renewal, or substitute thereof, and as to Letters Patents any reissue or re-examination thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other countries; and it has been and is hereby authorized and requested that the appropriate government agencies issue said Letters Patents to said GENENTECH, INC., in accordance with this Assignment.

Said ASSIGNOR covenants and agrees to cooperate with GENENTECH, INC., to enable said GENENTECH, INC. to enjoy to the fullest extent the right, title and interest herein conveyed in the United States and foreign countries. Such cooperation by said ASSIGNORS includes prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by said GENENTECH, INC., (a) for perfecting the right, title and interest herein conveyed; (b) for prosecuting any of said applications; (c) for filing and prosecuting applications for reissuance of any of said patents; (d) for interference or other priority proceedings involving said invention; and (e) for legal proceedings involving said invention and any applications therefor and any patents granted thereon, including without limitation opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by said ASSIGNORS in providing such cooperation shall be paid for by said GENENTECH, INC.


The terms and covenants of this assignment shall inure to the benefit of said GENENTECH, INC., its successors, assigns and other legal representatives, and shall be binding upon said ASSIGNOR, its respective heirs, legal representatives and assigns.

Said ASSIGNOR hereby warrants and represents that it has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

IN WITNESS WHEREOF I undersign as follows;

Essex, United Kingdom

Dated: 16/12/10



Dr. John Montana
For and on behalf of
Argenta Discovery 2009 Limited